Workflow
RAS(ON) inhibitors
icon
Search documents
Revolution Medicines(RVMD) - 2025 Q2 - Earnings Call Presentation
2025-08-06 20:30
On Target to Outsmart Cancer August 2025 © 2025 Revolution Medicines, Inc. 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and establi ...
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Globenewswire· 2025-08-06 20:02
Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY ...
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Globenewswire· 2025-07-30 20:05
Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company will report its financial results for Q2 2025 on August 6, 2025, after market close, followed by a webcast to discuss these results and corporate progress [1] Company Overview - Revolution Medicines is developing RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - The current R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are in clinical development [3] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [3] - Additional pipeline opportunities focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C) [3]
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Globenewswire· 2025-07-24 20:00
Core Insights - Revolution Medicines, Inc. has published a peer-reviewed research paper in Science detailing the discovery and development of zoldonrasib (RMC-9805), a selective covalent inhibitor targeting RAS(ON) G12D mutations in cancers [1][3] Group 1: Drug Development and Mechanism - Zoldonrasib targets RAS G12D mutations, which are prevalent in various cancers, including 92% of pancreatic ductal adenocarcinoma, 50% of colorectal cancer, and 30% of non-small cell lung cancer [2] - The drug employs a novel mechanism as a tri-complex inhibitor, successfully forming covalent bonds with RAS(ON) G12D proteins by utilizing a unique protein-protein interface [2][3] - Preclinical data indicate that zoldonrasib can drive significant tumor regressions in models with KRAS G12D mutations, showcasing its therapeutic potential [2][3] Group 2: Clinical Trials and Future Prospects - Zoldonrasib is currently in clinical trials, including a Phase 1 study (RMC-9805-001) evaluating its efficacy in patients with advanced solid tumors harboring KRAS G12D mutations [4] - Results from the NSCLC and PDAC studies have been presented at notable cancer research meetings, indicating ongoing evaluation and interest in the drug's performance [4] - The company is also developing additional RAS(ON) inhibitors, including daraxonrasib (RMC-6236) and elironrasib (RMC-6291), with plans for RMC-5127 (G12V-selective) to enter clinical development next [5]
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Globenewswire· 2025-06-30 12:00
Core Insights - Revolution Medicines and Summit Therapeutics have entered a clinical collaboration to evaluate the safety and efficacy of RAS(ON) inhibitors in combination with Summit's ivonescimab across multiple solid tumor types [1][2][3] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805) [4] - Summit Therapeutics is a biopharmaceutical oncology company dedicated to developing patient-friendly therapies aimed at improving quality of life and addressing unmet medical needs [5][6] Clinical Collaboration Details - The collaboration will assess combinations of RAS(ON) inhibitors with ivonescimab in three priority tumor types: RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC) [2] - Under the agreement, Summit will provide ivonescimab for clinical research, while Revolution Medicines will act as the study sponsor, with both companies retaining commercial rights to their respective compounds [2] Drug Development Insights - Initial evidence suggests that daraxonrasib and elironrasib can provide additive antitumor activity when combined with a PD-1 antibody in first-line treatment for RAS mutant non-small cell lung cancer [2] - The collaboration aims to explore the therapeutic potential of combining investigational drugs from Revolution's RAS(ON) inhibitor portfolio with Summit's advanced PD-1 / VEGF bispecific inhibitor [3]
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Globenewswire· 2025-04-27 16:05
Core Insights - Zoldonrasib, a RAS(ON) G12D-selective inhibitor, shows acceptable tolerability and promising initial antitumor activity in patients with KRAS G12D mutant non-small cell lung cancer (NSCLC) [1][2] Group 1: Clinical Data - New clinical data for zoldonrasib was presented at the American Association for Cancer Research (AACR) Annual Meeting, highlighting its potential as a treatment for NSCLC [1][2] - The Phase 1 study (RMC-9805-001) involved 90 solid tumor patients treated with 1200 mg once daily, demonstrating an acceptable safety profile consistent with previous data in pancreatic cancer [3] - The most common treatment-related adverse events (TRAEs) included nausea (39%), diarrhea (24%), vomiting (18%), and rash (12%), primarily Grade 1 or 2 in severity [3] Group 2: Efficacy Results - Preliminary antitumor activity was assessed in 18 efficacy-evaluable NSCLC patients, showing an objective response rate of 61% (11 patients) and a disease control rate of 89% (16 patients) [4] - The data indicates a high unmet need for new treatments in this patient population, as there are currently no approved targeted therapies for RAS G12D mutant cancers [5] Group 3: Company Overview - Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors [6] - The company is advancing zoldonrasib as a monotherapy and in combination therapies, aiming to provide innovative treatment options for hard-to-treat cancers [2][6]